Among the FDA’s foundational responsibilities is regulatory policy. At the highest levels of engagement, FDA staff and leadership work diligently and collaboratively with the public and private sectors, to protect and promote public health, advance scientific rigor, and support innovative products and pathways.

Recent Perspectives on Policy Topics

• 12/20/2021 Fulfilling Essential Public Health Needs in 2022
• 09/02/2021 FDA’s National Center for Toxicological Research Celebrates Half a Century of Cutting-Edge Research
• 07/22/2021 FDA Seeks Patient Insight: Call for Applications for the Patient Engagement Collaborative
• 07/21/2021 FDA's Budget: Medical Device Supply Chain and Shortages Prevention Program
• 07/19/2021 Global Regulators Envision Paradigm Shift Toward Inclusion of Pregnant and Breastfeeding Women in Clinical Research for Medicines and Vaccines
• 07/13/2021 One Year Later, the New Era of Smarter Food Safety Blueprint Makes Inroads in FDA’s Public Health Mission
• 07/12/2021 FDA to Discuss COVID-19’s Impact on Medical Product Operations at SBIA REdI Annual Conference
• 07/06/2021 FDA’s Budget: Data Modernization and Enhanced Technologies
• 06/24/2021 FDA’s Budget: Maternal and Infant Health and Nutrition
• 06/21/2021 FDA’s Budget: Advancing the Goal of Ending the Opioid Crisis
• 05/17/2021 Advancing FDA’s Mission by Targeting Key Areas for Regulatory Science Investment and Innovation
• 03/18/2021 FDA’s Ongoing Use of Inspectional Tools for Ensuring Access to Safe, Quality Food and Medical Products During the COVID-19 Pandemic
• 03/03/2021 FDA’s Data Modernization Action Plan: Putting Data to Work for Public Health
• 03/01/2021 Rare Disease Day 2021: FDA Shows Sustained Support of Rare Disease Product Development During the Public Health Emergency
• 01/19/2021 Unleashing the Power of FDA Data to Support COVID-19 Vaccine Distribution to Food and Agriculture Workers
• 01/15/2021 Accelerating the Adoption of Advanced Manufacturing Technologies to Strengthen Our Public Health Infrastructure
• 01/13/2021 Pandemic Response, Pandemic Preparation
• 01/08/2021 Better Data for a Better Understanding of the Use and Safety Profile of Cannabidiol (CBD) Products
• 12/30/2020 2020 at FDA: A Year of Unparalleled Contributions to Public Health
• 11/23/2020 Why the United States-Mexico-Canada Agreement is Important to FDA
• 10/19/2020 FDA’s Technology Modernization Action Plan Accelerates the Path to Enhancing and Promoting “People First” Public Health
• 10/07/2020 A Culture of Responsibility: Laboratory Safety at the FDA
• 09/29/2020 A Closer Look at the FDA’s Center for Devices and Radiological Health’s Unprecedented Efforts in the COVID-19 Response
• 09/11/2020 The FDA’s Scientific and Regulatory Oversight of Vaccines is Vital to Public Health
• 08/31/2020 Import Screening Pilot Unleashes the Power of Data and Leverages Artificial Intelligence
• 08/03/2020 Investing in Advanced Manufacturing to Support Public Health Preparedness
• 07/07/2020 FDA’s Continued Commitment to the Safety and Security of Our Laboratories
• 07/20/2020 FDA Protects Patients and Consumers from Fraud During COVID-19
• 07/14/2020 FDA’s Coronavirus Treatment Acceleration Program
• 06/25/2020 Partnering with the European Union and Global Regulators on COVID-19
• 06/23/2020 FDA Maintains the Pace of Meeting Its Goals on Applications for Medical Products During the Pandemic
• 06/02/2020 Pandemic Challenges Highlight the Importance of the New Era of Smarter Food Safety
• 05/29/2020 Bringing a Cancer Doctor’s Perspective to FDA’s Response to the COVID-19 Pandemic
• 05/18/2020 COVID-19 Supply Chain Update: Importation of Vital Food and Medical Products
• 05/04/2020 Insight into FDA’s Revised Policy on Antibody Tests: Prioritizing Access and Accuracy
• 04/22/2020 A Decade of FDA Advancing Health Equity
• 04/20/2020 The Path Forward: Coronavirus Treatment Acceleration Program
• 04/10/2020 A Perspective on the FDA’s COVID-19 Response
• 02/21/2020 Rare Disease Day 2020: FDA Continues Important Work on Treatments for Rare Diseases
• 11/07/2019 Patient Perspective Is Vital to FDA's Work
• 10/17/2019 Expanding Criminal Enforcement Operations Globally to Protect Public Health
• 10/03/2019 FDA's Critical Focus on Women's Health
• 09/19/2019 FDA’s Comprehensive Response to HIV - Part II
• 09/18/2019 FDA's Comprehensive Response to HIV - Part 1
• 08/27/2019 Delivering Promising New Medicines Without Sacrificing Safety and Efficacy
• 07/11/2019 Ensuring Patient Safety and Drug Manufacturing Quality Through Partnership with European Union Regulators
• 07/10/2019 How FDA is Regulating E-Cigarettes
• 06/25/2019 Forward Into the Past With FDA’s New History Exhibit
• 06/20/2019 Achievements in Tobacco Regulation Over the Past Decade and Beyond
• 06/14/2019 FDA is Committed to Sound, Science-based Policy on CBD
• 05/24/2019 2019 Spring Unified Agenda Reflects FDA’s Continuity and Consistency
• 04/30/2019 FDA Addresses Health Disparities Through Communication, Research, and Collaboration
• 04/09/2019 FDA Protecting the Nation Through Medical Countermeasures
• 04/03/2019 Understanding the Health Impact and Dangers of Smoke and 'Vapor'
• 04/02/2019 FDA Advancing Beneficial Animal Biotechnology Product Development
• 02/07/2019 Paving the Road to Produce Safety Rule Inspections
• 01/09/2019 The Future of FDA's Electronic Safety Surveillance
• 12/06/2018 FDA Proposes New Steps to Advance Clinical Testing to Deliver New Cures
• 12/04/2018 Fostering Collaborative Communities to Improve Patient Healthcare
• 11/29/2018 FDA's Global Efforts to Protect Patients and Consumers from Unsafe Products
• 11/19/2018 FDA is Advancing New Efforts to Address Drug Shortages
• 10/18/2018 Advancing Toward the Goal of Global Approval for Generic Drugs: FDA Proposes Critical First Steps to Harmonize the Global Scientific and Technical Standards for Generic Drugs
• 10/17/2018 Fall 2018 Unified Agenda: FDA's New Regulatory Work to Advance Health and Safety
• 09/26/2018 FDA Budget Matters: Advancing Innovation in Digital Health
• 09/11/2018 On-Farm Readiness Reviews Support Farmers as They Safeguard Produce
• 09/05/2018 New Program with Payors Aims to Accelerate Patient Access to Medical Devices
• 08/29/2018 FDA'€™s Comprehensive Effort to Advance New Innovations: Initiatives to Modernize for Innovation
• 08/02/2018 Advancing Tobacco Regulation to Protect Children and Families: Updates and New Initiatives from the FDA on the Anniversary of the Tobacco Control Act and FDA's Comprehensive Plan for Nicotine
• 07/16/2018 Protecting and Promoting Public Health: Advancing the FDA's Medical Countermeasures Mission
• 07/13/2018 FDA Budget Matters: Investing in Advanced Domestic Manufacturing
• 07/10/2018 FDA Budget Matters: A Cross-Cutting Data Enterprise for Real World Evidence
• 06/18/2018 Budget Matters: Infrastructure to Support Robust Generic Drug Competition
• 06/06/2018 FDA's New Efforts to Advance Biotechnology Innovation
• 05/31/2018 FDA Update on Traceback Related to the E. coli O157:H7 Outbreak Linked to Romaine Lettuce
• 05/14/2018 Addressing Needs of Patients While Stemming the Tide of the Opioid Crisis
• 05/09/2018 Spring Unified Agenda: FDA's Anticipated Upcoming Regulatory Work
• 05/02/2018 Food Information That's Pro Market and Pro Consumer
• 03/28/2018 We'€™re Committed to Guarding Against the Intentional Adulteration of Food and Implementing the New Rule Efficiently
• 03/21/2018 FDA is Using Innovative Methods to Prevent Illegal Products with Hidden Drug Ingredients from Entering the United States
• 02/26/2018 Taking New Steps to Meet the Challenges of Rare Diseases - FDA Marks the 11th Rare Disease Day
• 01/09/2018 Reflections on a Landmark Year for Medical Product Innovation and Public Health Advances and Looking Ahead to Policy in 2018
• 12/20/2017 You Spoke, FDA Listened: New Patient Engagement Collaborative, Call for Nominations
• 12/14/2017 Looking ahead: Some of FDA's major policy goals for 2018
• 12/14/2017 New Steps to Facilitate Beneficial Medical Device Innovation
• 12/11/2017 Advancing Policies to Promote Safe, Effective MedTech Innovation
• 12/01/2017 PEPFAR: FDA Approves 200th HIV/AIDS Therapy
• 11/29/2017 Advancing Medicinal Nicotine Replacement Therapies as New Drugs -€“ A new step in FDA'€™s comprehensive approach to tobacco and nicotine
• 11/15/2017 FDA Takes Steps to Build a Stronger Workforce
• 11/02/2017 FDA Widens Scope of Navigator - Information Tool for Expanded Access
• 10/23/2017 FDA Taking New Steps to Better Inform Physicians about Biosimilars Through Education about these Potentially Cost-Saving Options
• 10/03/2017 Expanded Access: FDA Describes Efforts to Ease Application Process
• 10/02/2017 Reducing the Hurdles for Complex Generic Drug Development
• 09/28/2017 FDA Takes Important Steps to Stem the Tide of Opioid Misuse and Abuse
• 09/12/2017 FDA is Advancing the Goals of the Orphan Drug Act
• 09/07/2017 FDA'™s plan to engage the public in the agency's new effort to strengthen and modernize FDA's regulatory framework
• 08/31/2017 New Steps To Strengthen FDA's Inspection And Oversight Of Drug Manufacturing
• 07/27/2017 FDA Announces New Steps to Empower Consumers and Advance Digital Healthcare
• 07/17/2017 Building a Strong FDA Workforce to Bring Scientific Advances to Patients
• 07/07/2017 How FDA Plans to Help Consumers Capitalize on Advances in Science
• 06/21/2017 FDA Working to Lift Barriers to Generic Drug Competition
• 06/15/2017 Fostering Medical Innovation: A Plan for Digital Health Devices
• 05/23/2017 FDA Commissioner Asks Staff for '€˜More Forceful Steps' to Stem the Opioid Crisis